Literature DB >> 27631359

Multitype Infections With Human Papillomavirus: Impact of Human Immunodeficiency Virus Coinfection.

Leslie Massad1, Marla Keller, Xianhong Xie, Howard Minkoff, Joel Palefsky, Gypsyamber DʼSouza, Christine Colie, Maria Villacres, Howard Strickler.   

Abstract

BACKGROUND: Human immunodeficiency virus (HIV) infection predisposes women to genital coinfection with human papillomaviruses (HPVs). Concurrent infection with multiple HPV types has been documented, but its frequency, correlates, and impact on development of precancer are poorly defined in HIV-seropositive women.
METHODS: Human immunodeficiency virus-seropositive women and -seronegative comparison women were enrolled in a cohort study and followed every 6 months from 1994 to 2006. Cervicovaginal lavage samples were tested for HPV types using polymerase chain reaction amplification with MY09/MY11 consensus primers followed by hybridization with consensus and HPV type-specific probes. Analyses were performed using generalized estimating equations.
RESULTS: Multitype HPV infections were found in 594 (23%) of 2543 HIV-seropositive women and 49 (5%) of 895 HIV-seronegative women (P < 0.0001). Compared with HPV uninfected women, those with multiple concurrent HPV infections were more likely to be younger, nonwhite, and current smokers, with lower CD4 counts and HIV RNA levels. The average proportion of women with multitype HPV infections across visits was 21% in HIV-seropositive women and 3% in HIV-seronegative women (P <0.0001). Compared with infection with 1 oncogenic HPV type, multitype concurrent infection with at least 1 other HPV type at baseline did not measurably increase the risk of ever having cervical intraepithelial neoplasia 3+ detected during follow-up (odds ratio, 0.80; 95% confidence interval, 0.32-2.03, P = 0.65).
CONCLUSIONS: Concurrent multitype HPV infection is common in HIV-seropositive women and frequency rises as CD4 count declines, but multitype infection does not increase precancer risk.

Entities:  

Mesh:

Year:  2016        PMID: 27631359      PMCID: PMC5026395          DOI: 10.1097/OLQ.0000000000000501

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  13 in total

1.  Concurrent and sequential acquisition of different genital human papillomavirus types.

Authors:  K K Thomas; J P Hughes; J M Kuypers; N B Kiviat; S K Lee; D E Adam; L A Koutsky
Journal:  J Infect Dis       Date:  2000-09-05       Impact factor: 5.226

2.  Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women.

Authors:  J M Palefsky; H Minkoff; L A Kalish; A Levine; H S Sacks; P Garcia; M Young; S Melnick; P Miotti; R Burk
Journal:  J Natl Cancer Inst       Date:  1999-02-03       Impact factor: 13.506

Review 3.  The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench.

Authors:  Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

4.  The influence of multiple human papillomavirus types on the risk of genotype-concordant incident infections of the anus and cervix: the Hawaii HPV cohort study.

Authors:  Marc T Goodman; Katharine McDuffie; Brenda Y Hernandez; Lynne R Wilkens; Xuemei Zhu; Pamela J Thompson; Jeffrey Killeen; Lori Kamemoto; Yurii B Shvetsov
Journal:  J Infect Dis       Date:  2010-12-20       Impact factor: 5.226

5.  Human papillomavirus infections with multiple types and risk of cervical neoplasia.

Authors:  Helen Trottier; Salaheddin Mahmud; Maria Cecilia Costa; João P Sobrinho; Eliane Duarte-Franco; Thomas E Rohan; Alex Ferenczy; Luisa L Villa; Eduardo L Franco
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

6.  Persistence of concurrent infections with multiple human papillomavirus types: a population-based cohort study.

Authors:  Nicole G Campos; Ana Cecilia Rodriguez; Philip E Castle; Rolando Herrero; Allan Hildesheim; Hormuzd Katki; Jane J Kim; Sholom Wacholder; Jorge Morales; Robert D Burk; Mark Schiffman
Journal:  J Infect Dis       Date:  2011-01-21       Impact factor: 5.226

7.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Authors:  Susanne K Kjær; Kirsten Frederiksen; Christian Munk; Thomas Iftner
Journal:  J Natl Cancer Inst       Date:  2010-09-14       Impact factor: 13.506

8.  Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion?

Authors:  Jacolien van der Marel; Johannes Berkhof; Jaume Ordi; Aureli Torné; Marta Del Pino; Romy van Baars; Mark Schiffman; Nicolas Wentzensen; David Jenkins; Wim G V Quint
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

9.  Comparison of HPV DNA testing in cervical exfoliated cells and tissue biopsies among HIV-positive women in Kenya.

Authors:  Hugo De Vuyst; Michael H Chung; Iacopo Baussano; Nelly R Mugo; Vanessa Tenet; Folkert J van Kemenade; Farzana S Rana; Samah R Sakr; Chris J L M Meijer; Peter J F Snijders; Silvia Franceschi
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

Review 10.  Issues in optimising and standardising the accuracy and utility of the colposcopic examination in the HPV era.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  Ecancermedicalscience       Date:  2015-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.